The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Aprea Therapeutics, Inc(NASDAQ:APRE) 
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical d...
Website: http://www.aprea.com
Founded: 2006
IPO Price: $15 (Oct 03, 2019)
Full Time Employees: 13
CEO: Christian S. Schade
Sector: Healthcare
Industry: Biotechnology
Aprea Therapeutics Days Payable Outstanding ttm (DPO)
Aprea Therapeutics Op Cashflow Per Share ttm
Aprea Therapeutics Free Cashflow Per Share ttm
Aprea Therapeutics Cash Per Share ttm
Aprea Therapeutics P/S ratio ttm
Aprea Therapeutics (GAAP) P/E ratio ttm
Aprea Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.